Tonix Pharmaceuticals Holding Corp.

Leland Stanford Junior University

Aarhus Universitet

Trigemina, Inc.

Elgan Pharma Ltd

Tonix Pharma Limited

Dean Carson

David C Yeomans

Ramachandran Thirucote

Erik Nguyen Nielsen

Karen J Parker

Marc Pentopoulos

Antonio Y Hardan

Michael Winterdahl

Steen Jakobsen

Disclosed are methods and compositions for the treatment of autism spectrum disorder, related disorders and symptoms of such disorders, comprising co-administration of an oxytocin peptide and magnesium ions. Co-administration of an oxytocin peptide and magnesium ions results in a synergistic or enhanced effect on reducing social and communication deficits in a patient suffering from an autism spectrum disorder.

Magnesium-containing oxytocin formulations and methods of use

Disclosed areN-oxytocin molecules, methods of manufacture ofN-oxytocin molecules and methods of use ofN-oxytocin molecules in the determination of the distribution and kinetics ofN-oxytocin molecules after craniofacial or other application methods.

Labeled oxytocin and method of manufacture and use

Provided herein are methods for treating, reducing and/or ameliorating symptoms of autism spectrum disorder (ASD) in a subject, where at least one measure of social impairment, anxiety, or repetitive behaviors is treated and/or ameliorated. Aspects include intranasally administering arginine vasopressin (AVP), or an analog of vasopressin, to a subject (e.g., a child between 6 and 12 years of age and having endogenous pre-treatment levels between about 0.045 and about 4.028 pg/mL, where the mean was 1.324 pg/mL). In children having high pre-treatment blood levels of AVP (e.g., about 25% or more above the mean pre-treatment AVP blood levels of the treatment group; or having pre-treatment blood vasopressin levels greater than 1.324 pg/mL), the treatment was enhanced. Because no difference in pre-treatment blood AVP levels was observed between control and ASD subjects, it was surprising that AVP treatment was more effective in subjects having high pre-treatment AVP levels.

Intranasal vasopressin treatment of social deficits in autism

Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treatment of pain (such as migraine headache) comprising co-administration of an oxytocin peptide and a magnesium salt.

Disclosed are oxytocin compositions having a therapeutically effective amount of oxytocin, an analog or derivative of oxytocin, or an oxytocin receptor agonist for the treatment of neonatal abstinence syndrome ('NAS') in a subject. Also disclosed are methods for the treatment of NAS by administering a therapeutically effective amount of oxytocin, an analog or derivative of oxytocin, or an oxytocin receptor agonist to a subject.

Growing community of inventors

Palo Alto, CA, United States of America

Dean Carson